Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services.

The EC has approved the extension of Stallergenes Greer’s Palforzia for the treatment of peanut allergy in toddlers.

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics.

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic disease.

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

With clinical trials facing multiple challenges, digital solutions could provide the answer. We identify the key trends to watch in 2025.

China's National Medical Products Administration has granted expanded approval to MSD's GARDASIL for use in males aged nine to 26 years.

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Actuate Therapeutics has gained OMPD from the EMA for elraglusib aimed at treating pancreatic ductal adenocarcinoma (PDAC).